PROGRAM LIVE SITES
- Meeting Information
- Course Directors
- Scientific Committee
- Associations and Affiliations
- TCTAP Live Interviews
- Daily Newspaper
- TCTAP Gallery



April 28 (Thu.), 2011
PCI is an Alternative to CABG for Left Main
Coronary Stenosis: PRECOMBAT Trial
Dr. Park presented the recent results of PRECOMBAT study and the future direction of percutaneous coronary intervention (PCI) for unprotected left main coronary artery (LMCA) stenosis. Data from the PRECOMBAT study were recently presented at the American College of Cardiology's 60th annual scientific session in New Orleans and published online ahead of print in the New England Journal of Medicine.The primary objective of the PRECOMBAT trial is to establish the safety and effectiveness of coronary stenting with the sirolimus-eluting alloon-expandable stent (Cypher, Cordis Corporation, Bridgewater, NJ) compared with bypass surgery for the treatment of an unprotected LMCA stenosis. The investigators noted that although coronary artery bypass grafting (CABG) has been considered the treatment of choice, PCI is increasingly used to treat unprotected LMCA stenosis.
The study randomly assigned patients with unprotected LMCA stenosis to undergo CABG (300 patients) or PCI with sirolimus-eluting stents (300 patients). Using a wide margin for noninferiority, they compared the groups with......
TCTAP 2011 Late Breaking Clinical Trials
Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal artery disease: 24-month update At TCT 2010, the one-year follow-up results of the ZILVER PTX trial were present-ed, which enrolled 479 patients with moderate to severe symptomatic femoropopliteal artery disease with lesions up to 14 cm. At 12 months, the patency rate was 83.1% with Zilver PTX and 67%
with angioplasty plus bare metal stent. Also, the patency rate was 89.9% with Zilver PTX and 73% with the bare metal stent in a head-to-head comparison of provisional stenting, demonstrating
that the drug effect was significant. Safety endpoints in the trial were also met. The ZILVER PTX trial will follow patients for up to five years. At the current TCT, it will be interesting to heart whether Zilver PTX has continued to show improved patency at 24 months. About this topic, Dr. Burket will answer all your questions in detail.......
Dr. Masakiyo Nobuyoshi Awarded The 1st TCTAP Award
'Master of the Masters'
Dr. Masakiyo Nobuyoshi, director of Kokura Memorial hospital, was recognized as the 1st recipient of TCTAP Award 'Master of the Masters' held on April 27 (Wed) at the Main Arena(Vista hall), the convention center of Sheraton Grand Walkerhill hotel. This year, organizing committee of ANGIOPLASTY SUMMIT-TCTAP, CardioVascular Research Foundation (CVRF), held a new TCTAP Award 'Master of the Masters' during this meeting. This Award seeks to honor and show appreciation to outstanding teachers and dedicators in education in the field of interventional cardiology. This meeting has all benefited from Dr. Nobuyoshi’s outstanding.....